An insight on drug resistance in Plasmodium vivax, a still neglected human malaria parasite



Plasmodium vivax has been considered for years as responsible for a mild form of malaria, due to the absence in the majority of its infections of the severe form of the disease, typical instead of the deadly human parasite P. falciparum. In the last decade, studies on vivax malaria have had a partial step ahead especially after the completion of the whole genome project, but there is still a gap of knowledge in the biology of this parasite. Moreover, the emergence of P. vivax antimalarial resistance in ‘80s and its subsequent spread in the Southeast Asia have indicated new concerns about the possibility to control this parasite. P. vivax drug resistance poses a major threat to endemic countries and without important international efforts, we could assist in a near future to the paradox of seeing different malaria co-endemic countries, that have successfully controlled/eliminated P. falciparum, still fighting against P. vivax

Share on



Mariangela L'Episcopia - Dipartimento DMI ISS

Edvige Perrotti - Dipartimento DMI ISS

Francesco Severini - Dipartimento DMI ISS

Stephane Picot - 2ICBMS CNRS 5246, SMITh, Malaria Research Unit, Campus Lyon-Tech La Doua, Lyon University, Lyon; Groupement Hospitalier Nord, Institut de Parasitologie et Mycologie Médicale, Hospices Civils de Lyon, Lyon.

Carlo Severini - Dipartimento DMI ISS

How to Cite
L'Episcopia, M., Perrotti, E., Severini, F., Picot, S., & Severini, C. (2020). An insight on drug resistance in Plasmodium vivax, a still neglected human malaria parasite. Annali dell’Istituto Superiore Di Sanità, 56(4), 403–408. Retrieved from
  • Abstract viewed - 352 times